BackSanthera Pharmaceuticals Holding AG Overview
Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG PEG Ratio

Santhera Pharmaceuticals Holding AG (SPHDF) has a PEG ratio of 14.39, above the Healthcare sector average of -6.46.

Get informed when a big investor buys or sells

+ Follow

PEG Ratio

14.39

PEG Ratio

14.39

The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.

PEG Ratio (Comparison Companies)

Loading

PEG Ratio History

Loading

PEG Ratio Comparison

Loading

Santhera Pharmaceuticals Holding AG (SPHDF) FAQ

Santhera Pharmaceuticals Holding AG's peg ratio stands at 14.39. That is above the Healthcare sector average of -6.46. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Santhera Pharmaceuticals Holding AG sits higher the Healthcare benchmark (-6.46) with a PEG ratio of 14.39. That is roughly 322.7% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 14.39 is attractive depends on Santhera Pharmaceuticals Holding AG's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Santhera Pharmaceuticals Holding AG's PEG ratio evolved across reporting periods, while the comparison chart places SPHDF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, PEG ratio is commonly used to spot outliers. Santhera Pharmaceuticals Holding AG's reading of 14.39 (sector avg -6.46) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.